ConductScience.org, home

Paper33112397

Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.

Schmid S and 35 others. JAMA Netw Open, 2020. Cited by 99 papers, by iCite.

Cite this record

ConductScience Library. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. Papers, record 33112397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33112397

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.
PubMed
Journal
JAMA Netw Open
PubMed
Year
2020
PubMed
Publication types
Journal Article, Multicenter Study
PubMed
Citations, by iCite
99
iCite
Relative citation ratio, by iCite
3.82
iCite
Revised in PubMed
2021-06-27
PubMed

Authors36

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schmid SSabine
2Omlin AAurelius
3Higano CCelestia
4Sweeney CChristopher
5Martinez Chanza NNieves
6Mehra NNiven
7Kuppen MCPMalou C P
8Beltran HHimisha
9Conteduca VVincenza
10Vargas Pivato de Almeida DDaniel
11Cotait Maluf FFernando
12Oh WKWilliam K
13Tsao CKChe-Kai
14Sartor OOliver
15Ledet EElisa
16Di Lorenzo GGiuseppe
17Yip SMSteven M
18Chi KNKim N
19Bianchini DDiletta
20De Giorgi UUgo

Source PubMed

See all 36 authorsDownload CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DNA Repair-Deficiency DisordersMajor topic
Drug TherapyMajor topic
Platinum CompoundsMajor topic
Prostatic NeoplasmsMajor topic
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Docetaxel
Humans
Male
Middle Aged
Paclitaxel
Retrospective Studies

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed

Source NIH RePORTER

Download CSV of grants

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Erratum in33206186Errors in Byline, Affiliations, and Conflict of Interest Disclosures.https://conductscience.org/library/papers/33206186PubMed
Comment in33112396Homologous Recombination DNA Repair Gene Aberrations-Are We More Alike Than Different?https://conductscience.org/library/papers/33112396PubMed

Download CSV of comments and corrections

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119805692Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.J Clin Oncol2009https://conductscience.org/library/papers/19805692PubMed
226903579Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.J Clin Oncol2016https://conductscience.org/library/papers/26903579PubMed
331515154Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.Lancet Oncol2019https://conductscience.org/library/papers/31515154PubMed
419179557Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.Ann Oncol2009https://conductscience.org/library/papers/19179557PubMed
519553641Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.N Engl J Med2009https://conductscience.org/library/papers/19553641PubMed
629713086Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.Nat Med2018https://conductscience.org/library/papers/29713086PubMed
728655541Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.Eur Urol2018https://conductscience.org/library/papers/28655541PubMed
815829966Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.Nature2005https://conductscience.org/library/papers/15829966PubMed
931958182Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.Cancer Sci2020https://conductscience.org/library/papers/31958182PubMed
1022722839The mutational landscape of lethal castration-resistant prostate cancer.Nature2012https://conductscience.org/library/papers/22722839PubMed
1132086346Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.Clin Cancer Res2020https://conductscience.org/library/papers/32086346PubMed
1231806540Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.Lancet Oncol2020https://conductscience.org/library/papers/31806540PubMed
1322981675Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.Eur Urol2013https://conductscience.org/library/papers/22981675PubMed
1432343890Olaparib for Metastatic Castration-Resistant Prostate Cancer.N Engl J Med2020https://conductscience.org/library/papers/32343890PubMed
1526510020DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.N Engl J Med2015https://conductscience.org/library/papers/26510020PubMed
1625058905Cisplatin in cancer therapy: molecular mechanisms of action.Eur J Pharmacol2014https://conductscience.org/library/papers/25058905PubMed
1728723506Biomarkers for Metastatic Castration-resistant Prostate Cancer (mCRPC): Yes or No? Predictive and Response Biomarkers Towards Precision Medicine in mCRPC.Eur Urol Focus2016https://conductscience.org/library/papers/28723506PubMed
1823118055Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.Cancer Res2012https://conductscience.org/library/papers/23118055PubMed
1915829967Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.Nature2005https://conductscience.org/library/papers/15829967PubMed
2030625039PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.J Clin Oncol2019https://conductscience.org/library/papers/30625039PubMed

See all 31 referencesDownload CSV of references

Cited by61

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 99 citations.

PMIDTitleJournalYearIn PapersSource
42423955
Platinum-based chemotherapy in metastatic castration-resistant prostate cancer: a narrative review and dual stratification framework based on HRR genotype and aggressive-variant/neuroendocrine phenotype.
Int Urol Nephrol2026https://conductscience.org/library/papers/42423955PubMed
42418738Shallow Whole-Genome Sequencing to Assess Genomic Instability and Predict Treatment Response in Metastatic Castration-Resistant Prostate Cancer.JCO Precis Oncol2026https://conductscience.org/library/papers/42418738PubMed
41789650Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions.Curr Opin Oncol2026https://conductscience.org/library/papers/41789650PubMed
41709957Studies on the functionality of the TC-NER ERCC6-M1097V protein variant frequently found in Louisiana patients with PCa upon UV damage.Front Oncol2025https://conductscience.org/library/papers/41709957PubMed
41373813Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment.Int J Mol Sci2025https://conductscience.org/library/papers/41373813PubMed
41304997YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41304997PubMed
40596117Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA.Sci Rep2025https://conductscience.org/library/papers/40596117PubMed
40558268Incidence and Risk Factors of Platinum-Based Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis.Curr Oncol2025https://conductscience.org/library/papers/40558268PubMed
40542015Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer.Sci Rep2025https://conductscience.org/library/papers/40542015PubMed
40293712Combining Spatial Transcriptomics, Pseudotime, and Machine Learning Enables Discovery of Biomarkers for Prostate Cancer.Cancer Res2025https://conductscience.org/library/papers/40293712PubMed
39793235Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations.Clin Genitourin Cancer2025https://conductscience.org/library/papers/39793235PubMed
39616467Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.Cancer2025https://conductscience.org/library/papers/39616467PubMed
39611376Prostate cancer and genetic contributions.Andrology2025https://conductscience.org/library/papers/39611376PubMed
39438537Synergistic effects of bloom helicase (BLM) inhibitor AO/854 with cisplatin in prostate cancer.Sci Rep2024https://conductscience.org/library/papers/39438537PubMed
39183332Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers.Cell Death Dis2024https://conductscience.org/library/papers/39183332PubMed
38730575Amino Terminal Acetylation of HOXB13 Regulates the DNA Damage Response in Prostate Cancer.Cancers (Basel)2024https://conductscience.org/library/papers/38730575PubMed
38453159Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Somatic or Germline Homologous Recombination Repair Gene Mutations: Phase II Single-Arm Trial.JMIR Res Protoc2024https://conductscience.org/library/papers/38453159PubMed
38425504Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.Ther Adv Urol2024https://conductscience.org/library/papers/38425504PubMed
38416404Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types.Clin Cancer Res2024https://conductscience.org/library/papers/38416404PubMed
38396858Precision Medicine in Castration-Resistant Prostate Cancer: Advances, Challenges, and the Landscape of PARPi Therapy-A Narrative Review.Int J Mol Sci2024https://conductscience.org/library/papers/38396858PubMed

See all 61 cited byDownload CSV of cited by

Genes10

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33112397

GET https://conductscience.org/api/papers/v1/33112397/authors?page=2